ロード中...
Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer
Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy. First‐ and second‐generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
AlphaMed Press
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6156184/ https://ncbi.nlm.nih.gov/pubmed/29650685 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0582 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|